Mazindol
Molecular structure of mazindol | |
3D representation of a mazindol molecule | |
| Clinical data | |
|---|---|
| Trade names | Mazanor, Sanorex |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Oral |
| Drug class | Serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI); Anorectic; Wakefulness-promoting agent; Stimulant |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 93% |
| Metabolism | Hepatic |
| Elimination half-life | 10–13 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.040.764 |
| Chemical and physical data | |
| Formula | C16H13ClN2O |
| Molar mass | 284.74 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Mazindol, sold under the brand names Mazanor and Sanorex, is an appetite suppressant which is used in the short-term treatment of obesity. It is also used off-label in the treatment of narcolepsy and cataplexy. The drug is taken orally.
Mazindol was developed by Sandoz-Wander in the 1960s. The US Food and Drug Administration approved mazindol in June 1973, but Novartis, the manufacturer, discontinued it in 1999 for reasons unrelated to its efficacy or safety.